Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
Subscribe To Our Newsletter & Stay Updated